Comparison of mortality and morbidity in patients with atrial fibrillation and heart failure with preserved versus decreased left ventricular ejection fraction.

Pubmed ID: 21855829

Journal: The American journal of cardiology

Publication Date: Nov. 1, 2011

Affiliation: Department of Internal Medicine, Wayne State University School of Medicine, Detroit, Michigan, USA.

MeSH Terms: Humans, Male, Female, Aged, United States, Age Factors, Hypertension, Randomized Controlled Trials as Topic, Proportional Hazards Models, Sex Factors, Atrial Fibrillation, Heart Failure, Disease Progression, Prognosis, Stroke, Stroke Volume, Anticoagulants, Warfarin, Patient Readmission

Authors: Afonso L, Rathod A, Jacob S, Badheka AO, Kizilbash MA, Bhardwaj A, Ali O

Cite As: Badheka AO, Rathod A, Kizilbash MA, Bhardwaj A, Ali O, Afonso L, Jacob S. Comparison of mortality and morbidity in patients with atrial fibrillation and heart failure with preserved versus decreased left ventricular ejection fraction. Am J Cardiol 2011 Nov 1;108(9):1283-8. Epub 2011 Aug 18.

Studies:

Abstract

Almost 50% of patients with congestive heart failure (HF) have preserved ejection fraction (PEF). Data on the effect of HF-PEF on atrial fibrillation outcomes are lacking. We assessed the prognostic significance of HF-PEF in an atrial fibrillation population compared to a systolic heart failure (SHF) population. A post hoc analysis of the National Heart, Lung, and Blood Institute-limited access data set of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial was carried out. The patients with a history of congestive HF and a preserved ejection fraction (EF >50%) were classified as having HF-PEF (n = 320). The patients with congestive HF and a qualitatively depressed EF (EF <50%) were classified as having SHF (n = 402). Cox proportional hazards analysis was performed. The mean follow-up duration was 1,181 ± 534 days/patient. The patients with HF-PEF had lower all-cause mortality (hazard ratio [HR] 0.62, 95% confidence interval [CI] 0.46 to 0.85, p = 0.003) and cardiovascular mortality (HR 0.56, 95% CI 0.38 to 0.84, p = 0.006), with a possible decreased arrhythmic end point (HR 0.39, 95% CI 0.16 to 1.006, p = 0.052) than did the patients with SHF. No differences were observed for ischemic stroke (HR 1.08, 95% CI 0.48 to 2.39, p = 0.86), rehospitalization (HR 0.89, 95% CI 0.75 to 1.07, p = 0.24), or progression to New York Heart Association class III-IV (odds ratio 0.80, 95% CI 0.42 to 1.54, p = 0.522). In conclusion, although patients with HF-PEF have better mortality outcomes than those with SHF, the morbidity appears to be similar.